Lptx stock zacks
Leap Therapeutics, Inc. (LPTX) Latest Stock News ... Get the latest Leap Therapeutics, Inc. (LPTX) stock news and headlines to help you in your trading and investing decisions. Zacks. Leap Therapeutics Surges on License Agreement With BieGene LPTX | Leap Therapeutics Inc. Profile | MarketWatch Oct 29, 2019 · Leap Therapeutics Inc. company facts, information and stock details by MarketWatch. View LPTX business summary and other industry information. Leap Therapeutics (NASDAQ:LPTX) Upgraded by Zacks ...
LPTX Stock Price, Forecast & News (Leap Therapeutics)
LPTX Stock Price, Forecast & News (Leap Therapeutics) Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a Leap Therapeutics, Inc. (LPTX) Stock Analysis & News ... Get breaking news and analysis on Leap Therapeutics, Inc. (LPTX) stock, price quote and chart, trading and investing tools. at Zacks.com (May 10, 2018) Leap Therapeutics, Inc. Common Stock (LPTX) Earnings ... Find the latest Earnings Report Date for Leap Therapeutics, Inc. Common Stock (LPTX) at Nasdaq.com. Looking for additional market data? According to Zacks Investment Research, based on 3
Leap Therapeutics, Inc. Common Stock (LPTX) Earnings ...
Leap Therapeutics Inc (NASDAQ:LPTX) traded up 5.7% during trading on Friday . The company traded as high as $0.73 and last traded at $0.72, 116,526 shares were traded during mid-day trading. A decline of 76% from the average session volume of 494,729 shares. The stock had previously closed at $0.68. A number of research analysts […] Leap Therapeutics Inc (NASDAQ:LPTX) Short Interest Update ... Leap Therapeutics Inc (NASDAQ:LPTX) was the recipient of a significant decrease in short interest during the month of March. As of March 13th, there was short interest totalling 1,742,400 shares, a decrease of 5.3% from the February 27th total of 1,840,000 shares. Approximately 12.0% of the shares of the company are short sold. Based on […] Leap Therapeutics (LPTX) Stock Price History | wallmine Feb 05, 2019 · Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Find the latest Leap Therapeutics, Inc. (LPTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Zacks.com featured highlights include
Leap Therapeutics (NASDAQ:LPTX) Trading 5 ... - Stock Observer Leap Therapeutics Inc (NASDAQ:LPTX) traded up 5.7% during trading on Friday . The company traded as high as $0.73 and last traded at $0.72, 116,526 shares were traded during mid-day trading. A decline of 76% from the average session volume of 494,729 shares. The stock had previously closed at $0.68. A number of research analysts […] Leap Therapeutics Inc (NASDAQ:LPTX) Short Interest Update ...
09-27 zacks.com Chicago, IL – September 27, 2019 - Stocks in this week’s article are Columbia Sportswear Company (COLM - Free Report) , American Woodmark Corp. (AMWD - Free Report) , DICK'S Sporting Goods Inc. (DKS - Free Report) , Alder BioPharmaceuticals Inc. (ALDR - Free Report) and Leap Therapeutics Inc. (LPTX - Free Report) . LPTX AMWD
LPTX: Get the latest Leap Therapeutics stock price and detailed information including LPTX news, historical charts and realtime prices. Leap Therapeutics, Inc. (LPTX) Latest Stock News ... Get the latest Leap Therapeutics, Inc. (LPTX) stock news and headlines to help you in your trading and investing decisions. Zacks. Leap Therapeutics Surges on License Agreement With BieGene
LPTX Stock Price, Forecast & News (Leap Therapeutics) Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a Leap Therapeutics, Inc. (LPTX) Stock Analysis & News ...